Core Viewpoint - The conference on cutting-edge technologies in cell and gene therapy highlighted the industry's innovative development paths and trends, emphasizing the potential of these therapies in treating tumors and rare diseases, positioning them as a key engine for the future of biomedicine [1][4]. Group 1: Industry Trends and Developments - The conference featured discussions on the advancements in stem cell drug development, particularly in applications for osteoarthritis, graft-versus-host disease, and Crohn's disease, indicating a shift from basic research to industrial application [3]. - mRNA nucleic acid drugs were identified as a breakthrough approach for personalized treatment, with significant advantages in oncology and neurodegenerative diseases, alongside a vision for AI-driven automated mRNA drug manufacturing [3]. - The integration of artificial intelligence into life sciences is expected to broaden market prospects for advanced therapies, as highlighted by experts analyzing the domestic and international development of cell and gene therapies [3][4]. Group 2: Regional Industry Growth - Zhuhai has over 380 biopharmaceutical companies, including 116 large-scale enterprises and 9 listed companies, indicating a robust industry presence [5]. - The biopharmaceutical industry in Zhuhai is projected to exceed 30 billion yuan in 2024, with notable companies in the cell and gene therapy sector, such as Chengnuo Regeneration and Aimsitan, showcasing strong competitive innovation [5]. - The conference served as a platform for fostering collaboration across the industry chain, promoting innovation and development in Zhuhai's biopharmaceutical sector [4].